Diabetes Translational Research Core

糖尿病翻译研究核心(DTRC)服务于DRC的一项主要使命；即，提供 将基于实验室的糖尿病发现和设备技术引入临床所需的基础设施 环境，以改善护理，减少糖尿病并发症，并最终减少 终生糖尿病。此外，DTRC还帮助耶鲁大学成为首屈一指的 世界上糖尿病临床和转化研究的机构，如许多 我们的调查人员在本批款期内发表的报告。DTRC支持尖端技术，基础广泛 近年来，翻译研究项目已扩大到包括以下领域： 糖尿病技术(CGM和胰岛素闭合给药系统)；功能磁共振成像、磁共振波谱和 宠物研究；T1D的新免疫疗法，以及参与T1和T2D注册和新的 美国国立卫生研究院赞助的多中心临床试验。耶鲁大学翻译研究项目组合的显著扩张 DTRC和耶鲁分析科学中心之间的协同作用也使之成为可能 (YCAS)、耶鲁临床调查中心(YCCI)和其他支持翻译的耶鲁资源 研究。DTRC在下一个资助期的目标是：1.提供专门的研究 基础设施(训练有素的人员、获得设备、实验室资源、研究设施)以及 对研究人员进行复杂的糖尿病相关研究以及临床试验所需的培训 糖尿病和相关的代谢紊乱。2.与YCAS和Yale Joint Data Analytics合作 支持制订协议和赠款；数据管理和数据分析；以及利用 耶鲁大学电子健康记录(EHR)的使用，以增强刚果民主共和国调查人员识别和登记患者的能力 进入研究并分析有关卫生保健提供绩效的数据。3.与基督教青年会合作支持 参与IRB文件准备的刚果民主共和国调查人员；预算谈判；临床试验协议；临床试验。gov 糖尿病患者在T1D交换中心和儿科糖尿病联盟的注册和登记 T2D注册表。DTRC支持的研究涵盖了糖尿病相关疾病的所有范围 (例如，T1和T2D和肥胖)；涉及人类整个一生的受试者(即，儿科和医学)， 测试新药、设备和行为干预的有效性和安全性；并描述潜在的 代谢改变的基础和大脑在预防低血糖和饮食紊乱中的作用。 DTRC的强大领导与我们老年糖尿病的国际地位相结合 调查人员和不断涌入的聪明热情的年轻调查人员提供了保证 在下一批资助期内，该中心的表现会继续维持在高水平。

The Diabetes Translational Research Core (DTRC) serves a key mission of the DRC; namely, to provide the infrastructure needed to bring laboratory based diabetes discoveries and device technologies into the clinical setting so as to improve care, diminish diabetes complications and ultimately diminish the prevalence of diabetes across the life-span. Moreover, the DTRC has assisted in establishing Yale as one of the premier institutions in the world for clinical and translational research in diabetes, as illustrated by the many publications by our investigators during the current grant period. DTRC support of cutting edge, broadly based translational research programs has been expanded in recent years to include areas such as advances in diabetes technologies (CGM and closed-loop insulin delivery systems); functional MRI, MR Spectroscopy and PET studies; and new immune-therapeutics for T1D, as well as participation in T1 and T2D Registries and new NIH-sponsored multi-center clinical trials. The remarkable expansion of Yale’s translational research portfolio has also been made possible by the synergy between the DTRC and the Yale Center for Analytic Science (YCAS), the Yale Center for Clinical Investigation (YCCI) and other Yale resources that support translational research. The aims of the DTRC during the next grant period are: 1. To provide specialized research infrastructure (trained personnel, access to equipment, laboratory resources, research facilities) as well as the training needed for investigators to carry out complex diabetes-related studies as well as clinical trials in diabetes and related metabolic disorders. 2. To partner with YCAS and the and the Yale Joint Data Analytics Team (JDAT) to support protocol and grant development; data management and data analyses; and utilization of Yale’s Electronic Health Record (EHR) to enhance DRC investigators’ capacity to identify and enroll patients into studies and to analyze data on health care delivery performance. 3. To partner with the YCCI to support DRC investigators in IRB document preparation; budget negotiations; clinical trial agreements; clinicaltrials.gov registration; and enrollment of diabetes patients in the T1D Exchange and the Pediatric Diabetes Consortium T2D Registries. Investigations supported by the DTRC span the entire range of diabetes related disorders (e.g., T1 and T2D and obesity); involve human subjects over the entire life-span (i.e., pediatrics and medicine), test the efficacy and safety of new drugs, devices and behavioral interventions; and describe the underlying basis of metabolic alterations and the role of the brain in the prevention of hypoglycemia and disorder eating. The strong leadership of the DTRC in combination with the international stature of our senior diabetes investigators and the continuing influx of bright and enthusiastic young investigators provides assurance that the DTRC will continue to perform at a high level during the next grant period.